Literature DB >> 8286835

Primary Sjögren's syndrome with subcortical dementia.

N Kawashima1, R Shindo, M Kohno.   

Abstract

A 48-year-old man with primary Sjögren's syndrome (P-SS) developed subcortical dementia, characterized by forgetfulness, poor attention and concentration, slowness of thought process, difficulty to manipulate acquired knowledge, introversive and hostile personality change and inactivity. These were improved by corticosteroid treatment. Magnetic resonance imaging (MRI) revealed small lesions in the subcortical and periventricular white matter. An electroencephalogram (EEG) revealed short runs of theta activities in bilateral parietal areas. Latency of P300 shortened in accordance with clinical improvement. These findings suggest that the cognitive and neuropsychiatric manifestations in P-SS are included in a spectrum of organic brain dysfunction and are treatable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8286835     DOI: 10.2169/internalmedicine.32.561

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

Review 1.  Insights into the role of immune activation in HIV neuropathogenesis.

Authors:  Suzanne Gartner; Yiling Liu
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

2.  Neurological Disorders in Primary Sjögren's Syndrome.

Authors:  Gabriel J Tobón; Jacques-Olivier Pers; Valérie Devauchelle-Pensec; Pierre Youinou
Journal:  Autoimmune Dis       Date:  2012-03-05

3.  Beyond the Glands: An in-Depth Perspective of Neurological Manifestations in Sjögren's Syndrome.

Authors:  Alexandria Voigt; Sukesh Sukumaran; Cuong Q Nguyen
Journal:  Rheumatology (Sunnyvale)       Date:  2014

4.  Population-based study suggests an increased risk of Alzheimer'sdisease in Sjögren's syndrome.

Authors:  Po-Chou Liliang; Cheng-Loong Liang; Kang Lu; San-Nan Yang; Meng-Tsang Hsieh; Yi-Cheng Tai; Kuo-Wei Wang
Journal:  Clin Rheumatol       Date:  2017-12-14       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.